Abstract
The present study aimed to investigate the effects of octreotide (OCT) on the reversal of resistance of cisplatin-resistant cancer cells and on enhancement of the cisplatin sensitivity of cancer cells.
The 3-(4,5-dimethylthiazol-2-yl)-2-5-diphenyltetrazolium bromide method and flow cytometry were used to investigate the effect of cisplatin, OCT or the combination of these two compounds on the proliferation and apoptosis of SKOV3/DDP cells.
Real-time, quantitative RT-PCR was used to detect the mRNA expression of SSTR2, MDR1, MRP2, GST-π and EGFR in SKOV3/DDP cells following OCT treatment.
At the concentration of 2.5-20 μg/ml, OCT significantly reduced the IC(50) value (P<0.05) and promoted apoptosis (P<0.05) in the SKOV3/DDP cells in response to cisplatin.
The synergistic effect of OCT and cisplatin on SKOV3/DDP cell proliferation was observed. SSTR2 was expressed on the SKOV3/DDP cell surface.
OCT increased GST-π expression (P<0.05) and reduced MRP2 and EGFR expression (P<0.05) in a dose-dependent manner. However, it had no effect on the expression of MDR1 (P>0.05).
It is suggested that OCT inhibits ovarian cancer proliferation and promotes apoptosis, via the cell surface expression of SSRT2, and reverses cisplatin resistance through the inhibition of MRP2 and EGFR expression.
See also:
- Somatostatin in oncology, the overlooked evidences;
- Pancreatic Adenocarcinoma: clinical records on 17 patients treated with Di Bella's Method;
- Complete objective response to biological therapy of plurifocal breast carcinoma.